{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:28:46Z","timestamp":1789576126333,"version":"build-2803163510"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Lessons Learned<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced germ cell tumors are associated with poor prognosis. We investigated the role of pembrolizumab in patients with advanced germ cell tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed a prespecified cohort of an open-label, phase II clinical trial in which patients with advanced germ cell tumors were treated with pembrolizumab (200 mg) intravenously every 21\u2009days. The endpoints of the study were the non-progression rate (NPR) at 27\u2009weeks, safety, and tolerability. An NPR &amp;gt;20% was considered successful and worthy of further pursuit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From August 2016 to February 2018, 12 patients (10 men, 2 women) were treated (median age, 35\u2009years [range, 22\u201363\u2009years]; median number of prior systemic therapies, 3.5 [range, 2\u20137]; median number of metastatic sites, 3 [range, 2\u20138]). Overall, pembrolizumab was well tolerated. One patient experienced both grade 1 immune-related skin rash and grade 3 immune-related pneumonitis. No patient died from toxicity. Three patients had radiographic stable disease that lasted for 10.9 months, 5.5 months, and 4.5 months, respectively. No objective response was noted. The median progression-free survival was 2.4 months (95% confidence interval [CI], 1.5\u20134.5 months), and the median overall survival was 10.6 months (95% CI, 4.6\u201327.1 months). The 27-week NPR was 9.0% (95% CI, 0.23\u201341.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, pembrolizumab was safe and had limited antitumor activity in these patients. In the advanced, metastatic setting, tumor profiling to understand the mechanisms of resistance to immunotherapy and innovative clinical trials to identify efficacious combination regimens rather than off-label use of pembrolizumab are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13682","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T23:57:04Z","timestamp":1611532624000},"page":"558-e1098","source":"Crossref","is-referenced-by-count":40,"title":["Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":false,"given":"Apostolia-Maria","family":"Tsimberidou","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Hiep","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Faraz","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"2022020214224933800_onco13682-bib-0001","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/iju.13519","article-title":"Current knowledge of risk factors for testicular germ cell tumors","volume":"25","author":"Fukawa","year":"2018","journal-title":"Int J Urol"},{"key":"2022020214224933800_onco13682-bib-0002","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.critrevonc.2019.09.005","article-title":"Targeted treatment approaches in refractory germ cell tumors","volume":"143","author":"Galvez-Carvajal","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022020214224933800_onco13682-bib-0003","author":"U.S. Food and Drug Administration"},{"key":"2022020214224933800_onco13682-bib-0004","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022020214224933800_onco13682-bib-0005","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.ejrad.2015.03.017","article-title":"Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment","volume":"84","author":"Nishino","year":"2015","journal-title":"Eur J Radiol"},{"key":"2022020214224933800_onco13682-bib-0006","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0426-7","article-title":"Trial Reporting in Immuno-Oncology (TRIO): An American society of clinical oncology-society for immunotherapy of cancer statement","volume":"6","author":"Tsimberidou","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2022020214224933800_onco13682-bib-0007","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2022020214224933800_onco13682-bib-0008","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"2022020214224933800_onco13682-bib-0009","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10637-019-00805-4","article-title":"Phase II study of avelumab in multiple relapsed\/refractory germ cell cancer","volume":"37","author":"Mego","year":"2019","journal-title":"Invest New Drugs"},{"key":"2022020214224933800_onco13682-bib-0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br J Cancer"},{"key":"2022020214224933800_onco13682-bib-0011","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdv574","article-title":"Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors","volume":"27","author":"Cierna","year":"2016","journal-title":"Ann Oncol"},{"key":"2022020214224933800_onco13682-bib-0012","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1396403","article-title":"Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1\/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials","volume":"7","author":"Huang","year":"2018","journal-title":"Oncoimmunology"},{"key":"2022020214224933800_onco13682-bib-0013","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2022020214224933800_onco13682-bib-0014","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2022020214224933800_onco13682-bib-0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: A decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"key":"2022020214224933800_onco13682-bib-0016","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1634\/theoncologist.2018-0430","article-title":"Genomic features for therapeutic insights of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors and comparison with gonadal counterpart","volume":"24","author":"Necchi","year":"2019","journal-title":"The Oncologist"},{"key":"2022020214224933800_onco13682-bib-0017","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/TP.0b013e3181a75633","article-title":"Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege","volume":"87","author":"Cheng","year":"2009","journal-title":"Transplantation"},{"key":"2022020214224933800_onco13682-bib-0018","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1158\/2326-6066.CIR-16-0087","article-title":"Clinical response of a patient to anti-PD-1 immunotherapy and the immune landscape of testicular germ cell tumors","volume":"4","author":"Shah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2022020214224933800_onco13682-bib-0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.01.033","article-title":"Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation","volume":"76","author":"Zschabitz","year":"2017","journal-title":"Eur J Cancer"},{"key":"2022020214224933800_onco13682-bib-0020","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1016\/j.clgc.2017.04.005","article-title":"Durable response to immune checkpoint blockade in a platinum-refractory patient with nonseminomatous germ cell tumor","volume":"15","author":"Chi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2022020214224933800_onco13682-bib-0021","author":"National Library of Medicine at the National Institutes of Health","year":"2020"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13682","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/558\/42367470\/oncolo_26_7_558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/558\/42367470\/oncolo_26_7_558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:29:08Z","timestamp":1643794148000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/7\/558\/6510489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,2,12]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13682","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,2,12]]}}}